• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

AZD-9291

Product ID A985134
Cas No. 1421373-65-0
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $80.40 In stock
100 mg $228.70 In stock
250 mg $401.80 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

AZD-9291 is an irreversible inhibitor of EGFR. It is approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous tyrosine kinase therapy, and more recently also in T790M negative NSCLC patients. Combination therapy with pemetrexed and cisplatin is currently being studied to delay or overcome resistance to AZD-9291 that is commonly experienced by patients after prolonged treatment.

Product Info

Cas No.

1421373-65-0

Purity

≥99%

Formula

C28H33N7O2

Formula Wt.

499.62

IUPAC Name

N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino}phenyl)acrylamide

Synonym

AZD 9291, AZD9291, Osimertinib, Mereletinib

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

A985134 MSDS PDF

Info Sheet

A985134 Info Sheet PDF

References

Bollinger M., Agnew A., et al. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm PRact. 24(5):279-388 (2018). PMID: 28565936.

La Monica S., Minari R., Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res. 38(1):222 (2019). PMID: 31138260.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only